[go: up one dir, main page]

DE60112766D1 - Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen - Google Patents

Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen

Info

Publication number
DE60112766D1
DE60112766D1 DE60112766T DE60112766T DE60112766D1 DE 60112766 D1 DE60112766 D1 DE 60112766D1 DE 60112766 T DE60112766 T DE 60112766T DE 60112766 T DE60112766 T DE 60112766T DE 60112766 D1 DE60112766 D1 DE 60112766D1
Authority
DE
Germany
Prior art keywords
valproic acid
pain
prevention
derivatives
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60112766T
Other languages
English (en)
Other versions
DE60112766T2 (de
Inventor
Mitchell Shirvan
Meir Bialer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of DE60112766D1 publication Critical patent/DE60112766D1/de
Publication of DE60112766T2 publication Critical patent/DE60112766T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60112766T 2000-08-17 2001-08-17 Verwendung von Derivaten der Valproinsäureamide und 2-Valproinsäureamide zur Behandlung und Prävention von Schmerzen und/oder Kopfschmerzen Expired - Lifetime DE60112766T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22597300P 2000-08-17 2000-08-17
US22597700P 2000-08-17 2000-08-17
US225977P 2000-08-17
US225973P 2000-08-17
PCT/US2001/025919 WO2002013766A2 (en) 2000-08-17 2001-08-17 Valproic acid derivatives for the treatment of pain

Publications (2)

Publication Number Publication Date
DE60112766D1 true DE60112766D1 (de) 2005-09-22
DE60112766T2 DE60112766T2 (de) 2006-03-30

Family

ID=26920105

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60112766T Expired - Lifetime DE60112766T2 (de) 2000-08-17 2001-08-17 Verwendung von Derivaten der Valproinsäureamide und 2-Valproinsäureamide zur Behandlung und Prävention von Schmerzen und/oder Kopfschmerzen

Country Status (21)

Country Link
US (3) US20020052418A1 (de)
EP (1) EP1311256B1 (de)
JP (1) JP2004505999A (de)
KR (1) KR100851955B1 (de)
CN (1) CN100462069C (de)
AT (1) ATE301995T1 (de)
AU (1) AU8830801A (de)
CA (1) CA2418455A1 (de)
CZ (1) CZ2004362A3 (de)
DE (1) DE60112766T2 (de)
DK (1) DK1311256T3 (de)
ES (1) ES2245377T3 (de)
HU (1) HUP0401867A2 (de)
IL (2) IL154470A0 (de)
MX (1) MXPA03001458A (de)
NO (1) NO20030724D0 (de)
NZ (1) NZ524687A (de)
PL (1) PL363041A1 (de)
SI (1) SI1311256T1 (de)
WO (1) WO2002013766A2 (de)
ZA (1) ZA200301427B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE327744T1 (de) * 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
WO2004071424A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries, Ltd. Immediate release formulation of n-(2-propylpentanoyl)glycinamide
EP1626707A4 (de) * 2003-02-05 2009-07-01 Yissum Res Dev Co Formulierung von n-(2-propylpentanoyl)-glycinamid mit verzögerter freisetzung und verwandten verbindungen
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
WO2005053667A1 (en) 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
AU2005232395B2 (en) 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006012603A2 (en) * 2004-07-22 2006-02-02 Nps Pharmaceuticals, Inc. Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
MX2007002269A (es) 2004-08-27 2007-06-15 Sanol Arznei Schwarz Gmbh Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos.
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
EP2462990B2 (de) 2006-06-15 2018-04-18 UCB Pharma GmbH Pharmazeutische Zubereitung, enthaltend Lacosamide und Levetiracetam, mit synergistischer antikonvulsiver Wirkung
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
ES2326355B1 (es) * 2008-02-25 2010-08-10 Centro Atlantico Del Medicamento, S.A. Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico.
KR101733189B1 (ko) * 2010-10-06 2017-05-08 (주)아모레퍼시픽 손톱 또는 발톱 성장 촉진용 조성물
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
US4301176A (en) * 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
CN1146421C (zh) * 1996-03-25 2004-04-21 伊莱利利公司 治疗疼痛的组合物以及药物在制备所述组合物中的应用
CN1152677C (zh) * 1996-08-30 2004-06-09 Nps药物有限公司 用异戊酸衍生物类cns抑制剂治疗强直、惊厥
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
HUP0102456A3 (en) * 1998-06-22 2003-07-28 American Biogenetic Sciences The use of valproic acid analog for the treatment and prevention of migraine and affective illness
EP1143967B1 (de) * 1999-01-19 2004-10-20 Ortho-Mcneil Pharmaceutical, Inc. Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache

Also Published As

Publication number Publication date
EP1311256B1 (de) 2005-08-17
WO2002013766A2 (en) 2002-02-21
NO20030724L (no) 2003-02-14
EP1311256A4 (de) 2004-03-24
EP1311256A2 (de) 2003-05-21
WO2002013766A3 (en) 2002-06-20
MXPA03001458A (es) 2004-05-04
NZ524687A (en) 2005-01-28
CZ2004362A3 (cs) 2005-01-12
CN100462069C (zh) 2009-02-18
ATE301995T1 (de) 2005-09-15
DE60112766T2 (de) 2006-03-30
US20020052418A1 (en) 2002-05-02
JP2004505999A (ja) 2004-02-26
IL154470A0 (en) 2003-09-17
DK1311256T3 (da) 2005-11-28
HUP0401867A2 (hu) 2004-12-28
US20040204495A1 (en) 2004-10-14
US20090281045A1 (en) 2009-11-12
SI1311256T1 (sl) 2005-12-31
KR20030036691A (ko) 2003-05-09
US8288442B2 (en) 2012-10-16
PL363041A1 (en) 2004-11-15
KR100851955B1 (ko) 2008-08-12
NO20030724D0 (no) 2003-02-14
ZA200301427B (en) 2004-02-23
CN1551762A (zh) 2004-12-01
ES2245377T3 (es) 2006-01-01
IL154470A (en) 2010-11-30
AU8830801A (en) 2002-02-25
CA2418455A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
EA200401365A1 (ru) Способы лечения илеуса
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
DE602004016841D1 (de) Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE454142T1 (de) Verbindungen zur behandlung von neuropathischen schmerzen und migräne
DE60310975D1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE60218726D1 (de) Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEB, IL